Blood-based biomarker may redefine future treatment for advanced melanoma
Circulating tumor DNA (ctDNA) is emerging as a blood-based biomarker for many solid tumor types, including melanoma. A new study that assessed ctDNA in the blood of patients with BRAF wild-type (BRAF WT) stage III and IV ...
Oct 4, 2023
0
23